A thymosin-β4 fragment marketed for recovery and tissue repair, often stacked with BPC-157.
Recovery claims in sport and the broader peptide-clinic market.
Preclinical biology cannot establish that grey-market TB-500 improves meaningful outcomes safely in humans.
Treat as an unapproved experimental substance, not routine recovery care; it is relevant to anti-doping rules.